Instituto de Biología y Medicina Experimental (IBYME)
IBYME is a Buenos Aires-based non-profit biomedical research institute founded in 1944, operating under CONICET and Fundación IBYME. It conducts basic and applied research across six areas and commercializes 50+ high-level technological services (STAN) plus spin-offs like Fecundis.
- Company typePrivate
- Founded1944
- HeadquartersBuenos Aires, Argentina
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Instituto de Biología y Medicina Experimental (IBYME) does
Instituto de Biología y Medicina Experimental (IBYME) is a non-profit biomedical research institute founded in 1944 by Nobel laureate Dr. Bernardo Houssay in Buenos Aires, Argentina, operating under a dual-dependence governance structure between CONICET (Argentina's national scientific and technical research council) and Fundación IBYME. The institute conducts basic and applied research across six areas — Cellular and Molecular Biology, Endocrinology, Immunology, Neurosciences and Behavior, Oncology, and Reproduction — supported by more than 30 specialized laboratories, an indexed publication archive of 85+ pages, and complementary facilities including a library, animal facility (Bioterio), and dedicated microscopy and flow cytometry services. Its commercialization arm is the STAN IBYME-CONICET platform (Servicios Tecnológicos de Alto Nivel), a portfolio of more than 50 high-level technological services including glycomics analysis via HPLC/UPLC-HILIC, ZEISS LSM 880 confocal microscopy with Airyscan, laser capture microdissection, flow cytometry, single-cell gene expression, isothermal titration calorimetry, in vitro and in vivo drug testing for cancer and Alzheimer's, IVF and embryo transfer, histology, and hormone radioimmunoassay. The institute also hosts technology-based spin-offs such as Fecundis, which commercializes HyperSperm sperm capacitation technology for assisted reproduction.
Revenue is generated through four streams: (1) government funding from CONICET for research positions and operations, (2) STAN service fees charged to external clients (companies, educational institutions, healthcare organizations, and other research entities) under quote-based pricing regulated by CONICET resolutions, (3) donations and grants through Fundación IBYME (including from Fundación René Barón and Fundación Williams), and (4) revenue from postgraduate courses, seminars, and training programs. Customer segments are diverse: internal scientific research community, external research organizations, graduate students, and pharmaceutical/biotechnology companies seeking preclinical services. Regulatory independence is enforced through an accredited Ethics Committee (CCE, since 2013, renewed 2025), RENIS registration for health research, and CICUAL oversight for animal research.
Instituto de Biología y Medicina Experimental (IBYME) firmographics
Firmographics- Name
- Instituto de Biología y Medicina Experimental (IBYME)
- Legal name
- Instituto de Biología y Medicina Experimental
- Website
- https://ibyme.org.ar
- Company type
- Private
- Founded year
- 1944
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- IBYME is a Buenos Aires-based non-profit biomedical research institute founded in 1944, operating under CONICET and Fundación IBYME. It conducts basic and applied research across six areas and commercializes 50+ high-level technological services (STAN) plus spin-offs like Fecundis.
- Ownership category
- akta.pro rank
Instituto de Biología y Medicina Experimental (IBYME) industry classification
Industry- Product category
- Biomedical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Research & Trial Central Laboratories (HLAFAMAL)
Keywords
Where Instituto de Biología y Medicina Experimental (IBYME) is headquartered
LocationHeadquarters
- HQ city
- Buenos Aires
- HQ country
- Argentina
- HQ region
- Latin America
Offices1 record
Markets served
Instituto de Biología y Medicina Experimental (IBYME) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations
Revenue model
- Public Funding (CONICET): As a CONICET research unit, IBYME receives government funding for scientific research, investigator positions, and operational costs through the Argentine National Scientific and Technical Research Council.
- Technological Services (STAN): IBYME provides over 50 high-level technological services to external clients including companies, educational institutions, healthcare providers, and research organizations. Services range from glycomics analysis, flow cytometry, microscopy, animal testing, consulting, and specialized research assistance.
- Foundation Support: Fundación IBYME supports the institute's operations through donations and grants, including equipment acquisition funding from private foundations such as Fundación René Barón and Fundación Williams.
- Educational Programs: The institute generates revenue through postgraduate courses, seminars, and training programs at undergraduate and graduate levels.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Instituto de Biología y Medicina Experimental (IBYME) product offering
Product offeringCore offering
IBYME is a non-profit biomedical research institute that conducts basic and applied scientific research across six core areas — cellular and molecular biology, endocrinology, immunology, neurosciences and behavior, oncology, and reproduction — operating more than 30 laboratories staffed by 88 employees. It commercializes its research infrastructure through the STAN platform, which offers 50+ specialized technological services to external research, pharmaceutical, and clinical clients, and develops proprietary translational products such as the HyperSperm sperm-selection device and the BIMOVA ovulation-prediction platform. Revenue is generated through STAN service fees, public research grants (CONICET), foundation donations, and tuition from postgraduate academic programs.
Product overview
IBYME operates as a dual-dependence research institute (CONICET – Fundación IBYME) established in 1944 under Nobel laureate Dr. Bernardo Houssay, conducting basic and applied research across six areas: Cellular and Molecular Biology, Endocrinology, Immunology, Neurosciences and Behavior, Oncology, and Reproduction. Its technology transfer arm is the STAN IBYME-CONICET (Servicios Tecnológicos de Alto Nivel) portfolio, a collection of 50+ high-level scientific services covering glycomics and structural analysis (glycosylation, monosaccharide, sialic acid speciation), cryopreservation, flow cytometry, confocal and laser capture microdissection microscopy, in vitro and in vivo drug efficacy/toxicity testing for cancer and Alzheimer's disease, single-cell gene expression analysis, behavioral testing, IVF and embryo transfer, isothermal titration calorimetry, histology, and hormone radioimmunoassay. Infrastructure is supported by complementary facilities including the Bernardo A. Houssay Library, an Animal Facility (Bioterio), Microscopy Service, and Flow Cytometry Service. Research governance is ensured by an Ethics Committee (accredited since 2013, renewed 2025) and a CICUAL (Institutional Committee for the Care and Use of Laboratory Animals). The institute also hosts technology-based companies (EBTs) such as Fecundis, which commercializes the HyperSperm sperm capacitation enhancement technology.
Differentiator
Problem solved
Functional benefit
Products and services
- STAN Technological Services Platform An integrated service platform offering 50+ specialized technological services (including cell culture, advanced microscopy, flow cytometry, proteomics, molecular biology, behavioral phenotyping, biobanking, and access to SPF animal facilities) for external research, pharmaceutical, biotechnology, and clinical clients seeking fee-based access to advanced biomedical infrastructure.
- HyperSperm A proprietary device/technology for selecting sperm cells with intact DNA, derived from IBYME's Reproduction research area, intended for use in assisted reproductive technology (ART) and clinical fertility applications.
- BIMOVA A proprietary platform/technology for predicting menstrual cycle phase and ovulation timing, derived from IBYME's Reproduction research area, intended for clinical, reproductive-health, and fertility applications.
- Postgraduate Academic Programs (Doctorado, Maestría, Especialización) Accredited postgraduate academic programs (doctoral, master's, and specialization degrees) in biomedical sciences, anchored in IBYME's 30+ research laboratories and delivered under CONICET academic oversight, intended for graduate students and early-career researchers seeking advanced biomedical research training.
- Preclinical and Translational Research Services Preclinical and translational research services spanning IBYME's six research areas (cellular and molecular biology, endocrinology, immunology, neurosciences and behavior, oncology, and reproduction), delivered to academic, clinical, pharmaceutical, and biotechnology clients through the STAN platform and direct collaborations.
Quantifiable outcome
- HyperSperm technology showed improved number and quality of embryos in multicenter IVF study
- +1 more outcomes
Companies that use Instituto de Biología y Medicina Experimental (IBYME)
Customer profileSegments4 records
Ideal customer profiles3 records
Instituto de Biología y Medicina Experimental (IBYME) technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Instituto de Biología y Medicina Experimental (IBYME) partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- FecundiscoreFecundis is a technology-based company (EBT - Empresa de Base Tecnológica) developed from IBYME research. The company commercializes HyperSperm technology for assisted reproduction, developed by IBYME researchers including Dr. Mariano Buffone. The company operates within IBYME facilities.
- Mercosur Southern Agencies AllianceminorIBYME hosts a Brazilian delegation visit as part of an alliance between Southern Mercosur agencies, indicating regional scientific collaboration.
- CONICETcoreIBYME operates as a dual-dependence research unit with CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Argentina's national scientific and technical research council. CONICET provides funding, researcher positions, and administrative oversight through Resolution D. No 3596/09 and related regulations.
- Fundación IBYMEcoreFundación IBYME is the founding partner that co-governs the institute alongside CONICET. The foundation supports IBYME's work since 1944, continuing the objectives established by founders Drs. Houssay, Braun Menéndez, and Foglia. Foundation provides equipment donations, course funding, and operational support.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Instituto de Biología y Medicina Experimental (IBYME) competitors and assessment
Company assessmentOthers
- WuXi AppTec: Global CRO/CDMO providing preclinical drug testing, biologics characterization, and genomics services. Comparable to IBYME's STAN portfolio (glycomics, in vitro proliferation assays, single-cell gene expression) in serving biopharma R&D workflows, though at global scale.
Broad incumbents
- IQVIA: Global clinical research and life sciences services provider spanning real-world data, lab services, and clinical trial support. Comparable to IBYME's role as a regulated laboratory services platform serving pharma/biotech clients, though operating as a large commercial incumbent.
- Charles River Laboratories: Global contract research organization offering preclinical drug efficacy and safety testing, including in vivo oncology and neuroscience models. Comparable to IBYME's STAN services for in vitro/in vivo antitumor and Alzheimer's drug testing (STAN codes 1010, 7666, 7667), though at vastly greater scale and as a commercial CRO rather than a public institute.
- Labcorp: Global clinical and diagnostic laboratory network with central laboratory capabilities supporting clinical trials and biomedical research. Comparable to IBYME's clinical laboratory functions such as the COVID-T T-cell response platform and SARS-CoV-2 neutralizing antibody assays (STAN 5718, 5604).
Regional players
- Instituto Pasteur de Montevideo: Uruguayan biomedical research institute affiliated with the global Pasteur Network, conducting research in immunology, infectious diseases, and structural biology. Comparable to IBYME as a Latin American regional biomedical research center with similar institutional structure and services portfolio.
- Fundação Oswaldo Cruz (Fiocruz): Brazilian public health and biomedical research institution operating under the Ministry of Health, with extensive labs, technology platforms, and graduate training programs. Comparable to IBYME as a large Latin American government-affiliated biomedical research and technology services organization.
Direct peers
- Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI): CONICET-affiliated Buenos Aires institute conducting research in molecular biology and genetics. Comparable to IBYME in governance structure (dual-dependence with CONICET), research scope, and role as a public-sector biomedical research hub in Argentina.
- Instituto Leloir: Buenos Aires-based biomedical research institute founded with CONICET support, focused on molecular biology, structural biology, and cell biology. Directly comparable to IBYME as a peer Argentine CONICET-dependent biomedical research center offering advanced technology platforms and graduate training.
- Instituto Pasteur de Buenos Aires: Buenos Aires-based research institute focused on microbiology, immunology, and infectious diseases, with historical Pasteur Institute affiliation. Directly comparable to IBYME as a peer Argentine biomedical research center with public-sector funding and a strong publication record.
Emerging players
- Fecundis: Technology-based company (EBT) incubated at IBYME that commercializes HyperSperm sperm capacitation technology for assisted reproduction. Comparable to IBYME as a spin-out emerging player leveraging IBYME's reproductive biology research infrastructure and demonstrating the institute's technology transfer model.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Instituto de Biología y Medicina Experimental (IBYME) social profiles
Digital presenceInstituto de Biología y Medicina Experimental (IBYME) compliance and trust
Trust signalCompliance1 record
Instituto de Biología y Medicina Experimental (IBYME) financial estimates
Financial estimateRevenue estimate
Valuation estimate
Instituto de Biología y Medicina Experimental (IBYME) leadership team
Management profileNumber of profiles
Instituto de Biología y Medicina Experimental (IBYME) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Instituto de Biología y Medicina Experimental (IBYME) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Instituto de Biología y Medicina Experimental (IBYME)
What does Instituto de Biología y Medicina Experimental (IBYME) do?
IBYME is a non-profit biomedical research institute that conducts basic and applied scientific research across six core areas — cellular and molecular biology, endocrinology, immunology, neurosciences and behavior, oncology, and reproduction — operating more than 30 laboratories staffed by 88 employees. It commercializes its research infrastructure through the STAN platform, which offers 50+ specialized technological services to external research, pharmaceutical, and clinical clients, and develops proprietary translational products such as the HyperSperm sperm-selection device and the BIMOVA ovulation-prediction platform. Revenue is generated through STAN service fees, public research grants (CONICET), foundation donations, and tuition from postgraduate academic programs.
Is Instituto de Biología y Medicina Experimental (IBYME) a public or private company?
Instituto de Biología y Medicina Experimental (IBYME) is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Instituto de Biología y Medicina Experimental (IBYME) founded?
Instituto de Biología y Medicina Experimental (IBYME) was founded in 1944. It employs 51 to 100 people.
Where is Instituto de Biología y Medicina Experimental (IBYME) based?
Instituto de Biología y Medicina Experimental (IBYME) is headquartered in Buenos Aires, Argentina, in the Latin America region.
How does Instituto de Biología y Medicina Experimental (IBYME) make money?
Four revenue lines are on record. Public Funding (CONICET) is the primary driver. The others are technological Services (STAN), foundation Support and educational Programs.
Who are Instituto de Biología y Medicina Experimental (IBYME)'s main competitors?
WuXi AppTec is listed as an others. Broad incumbents are IQVIA, Charles River Laboratories and Labcorp. Regional players are Instituto Pasteur de Montevideo and Fundação Oswaldo Cruz (Fiocruz). Direct peers are Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Instituto Leloir and Instituto Pasteur de Buenos Aires. Fecundis is listed as an emerging player.
Does Instituto de Biología y Medicina Experimental (IBYME) have an API?
No public API is recorded for Instituto de Biología y Medicina Experimental (IBYME).
What industry is Instituto de Biología y Medicina Experimental (IBYME) in?
Instituto de Biología y Medicina Experimental (IBYME)'s product category is Biomedical Research Services. Its primary akta.pro industry code is HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 541714 and its SIC code is 8731.